tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development … Delivering training on Quality Systems and ensuring data integrity across both paper-based and electronic systems. We are looking for: Significant experience in Quality Systems within the biopharmaceutical/pharmaceutical industry, with a strong understanding of GMP and regulatory standards. Proven background in Pharmaceutical QA, including audits, inspections, investigations, root cause analysis, and change control. Experience managing electronic Quality Management … we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. More ❯
tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development … we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. … we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. More ❯
related experience or equivalent experience required. Advanced degree (PhD, MBA, MD) strongly preferred. 10+ years of experience in competitive intelligence, commercial strategy, or business development within the biotech/pharma industry. Strong background in oncology highly preferred. Proven track record of influencing portfolio and program decisions through strategic insights and commercial acumen. Excellent communication and presentation skills - ability to present … understanding of drug development, clinical trial design, and commercialization pathways. Experience in a global, matrixed organization with cross functional leadership responsibilities. Excellent analytical abilities. Extensive experience in biotech/pharma via industry, banking or strategy consultancy roles. Understanding of scientific, clinical and market data to identify patterns and opportunities. Deep understanding of the drug development process. Expert knowledge of a More ❯
tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development … we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. … tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development More ❯
Business Development Manager Cable Containment Job Title: Business Development Manager Cable Containment Industry Sector: Food & Beverage, Pharmaceutical, Warehouse & Logistics, Heavy Industry, Industrial, Waste Water, Infrastructure, Cable Management, Cable Containment, Cable Support, Cable Ladders, Cable Trays, Mesh Trays, Steel Trunking, Steel Ladders, GRP Ladders, GRP Trays, M&E Consultants, Design Consultants, HVAC, Electrical Contractors, Electrical Distributors Area to be covered: South … and baskets 75% time winning specifications with design consultants and M&E consultants Remainder of time managing relationships with electrical contractors and distributors Steel products sold into food & beverage, pharmaceutical, warehousing & logistics, GRP products sols into waste water and infrastructure New business development roles, our client generates significant revenue in the Nordics but is relatively small (but growing) in the … Manager Cable Containment with: A proven track record in mechanical or electrical M&E specification sales Must have sold into at least one of the following sectors; food & beverage, pharmaceutical, warehousing & logistics, waste water or infrastructure Stable career history, role will suit someone looking for longevity New business hunter Comfortable in small (start-up) UK business with significant backing from More ❯
